Alpine Immune Sciences

Modern therapies targeting the immune synapse


Alpine Immune Sciences

Novel proteins created using directed evolution-based discovery platform


Alpine Immune Sciences

Helping patients with cancer and autoimmune disease


Modern therapies targeting the immune synapse

We create protein-based immunotherapies targeting the immune synapse to treat cancer, autoimmune/inflammatory disorders, and other diseases.

Alpine Immune Sciences capitalizes on our unique understanding of the immune synapse, using our directed evolution platform to engineer native immune system proteins for therapeutic benefit.

Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2018 Financial Results

First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program, ALPN-101

Completed $25 Million Private Placement

Strong Financial Position to Transition Two Lead Programs ALPN-101 and ALPN-202 into Patients

Read More

At Alpine Immune Sciences, we are applying our platform discovery technology to bring innovative new drugs to people living with cancer and autoimmune/inflammatory diseases

Directed Evolution Platform

Alpine’s powerful directed evolution platform is based upon proteins native to the immune synapse, engineering potentially novel “Variant immunoglobulin domains” or “vIgDs”. Our vIgDs can engage multiple targets simultaneously, can be significantly more potent then native proteins, and have the potential improve therapeutic outcomes for the treatment of cancer, autoimmune/inflammatory conditions, or infectious diseases.

Because vIgDs are based upon natural participants in the immune synapse, they potentially provide a mechanistic advantage over larger, more artificial constructs.

Lead Programs

ALPN-101 is a dual ICOS/CD28 antagonist being developed for the treatment of autoimmune and inflammatory diseases. Dosing has already begun in a Phase I healthy volunteer study, and we anticipate moving towards studies in acute GvHD and Psoriatic Arthritis.

ALPN-202 is a dual PD-L1/CTLA-4 antagonist with PD-L1 dependent CD28 costimulation being developed for the treatment of cancer. We anticipate filing an IND for ALPN-202 later in 2019.

Our Transmembrane Immunomodulatory Protein (TIP) program potentially enhances Engineered Cellular Therapies (ECTs) like CAR-T, TCR, and TIL. TIPs are based upon our core vIgD technology, but are engineered to become part of ECTs to potentially increase specificity, persistence, and/or efficacy.